A Somatostatin Receptor Subtype-3 (SST
Adolescent
Adult
Aged
Aged, 80 and over
Animals
Apoptosis
/ drug effects
Cell Proliferation
/ drug effects
Disease Models, Animal
Drug Evaluation, Preclinical
Female
Humans
Janus Kinases
/ metabolism
MAP Kinase Signaling System
/ drug effects
Male
Mice
Mice, Knockout
Middle Aged
Neuroendocrine Tumors
/ drug therapy
Peptides
/ chemistry
Phosphatidylinositol 3-Kinases
/ metabolism
Pituitary Neoplasms
/ drug therapy
Receptors, Somatostatin
/ agonists
Signal Transduction
Tumor Cells, Cultured
Young Adult
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 02 2020
15 02 2020
Historique:
received:
30
06
2019
revised:
08
09
2019
accepted:
14
10
2019
pubmed:
19
10
2019
medline:
18
11
2020
entrez:
19
10
2019
Statut:
ppublish
Résumé
Somatostatin analogues (SSA) are efficacious and safe treatments for a variety of neuroendocrine tumors, especially pituitary neuroendocrine tumors (PitNET). Their therapeutic effects are mainly mediated by somatostatin receptors SST Binding to SSTs and cAMP level determinations were used to screen a peptide library and identify SST We successfully identified the first SST This study demonstrates that SST
Identifiants
pubmed: 31624102
pii: 1078-0432.CCR-19-2154
doi: 10.1158/1078-0432.CCR-19-2154
doi:
Substances chimiques
Peptides
0
Receptors, Somatostatin
0
somatostatin receptor 3
0
Janus Kinases
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
957-969Informations de copyright
©2019 American Association for Cancer Research.